pharma · Unstable Angina Pectoris · Gastric Carcinoma · COLL
COLLEGIUM PHARMACEUTICAL
COLLEGIUM PHARMACEUTICAL, INC
Collegium Pharmaceutical is a pharma organization headquartered in Stoughton, USA. It trades on NYSE under ticker COLL. Primary therapeutic focus areas include Unstable Angina Pectoris, Gastric Carcinoma, aspirin-exacerb
100 Technology Center Dr, Stoughton, Massachusetts 02072, US HQ
617 Employees
Public company Type
COLL · NYSE Ticker
Company details
- Status
- Public
- HQ
- 100 Technology Center Dr, Stoughton, Massachusetts 02072, US
- Employees
- 617
- Programs
- 29
- Drugs
- 48
- Patents
- 28
De-escalation to ticagrelor 60 mg at day 30
Phase 3 · small molecule · Non ST Segment Elevation Acute Coronary Syndrome
De-escalation to ticagrelor 60 mg at day 30 for Non ST Segment Elevation Acute Coronary Syndrome is a Phase 3 program (small_molecule) at COLLEGIUM PHARMACEUTICAL, INC with 1 ClinicalTrials.gov record(s).
Internal code 2023/01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- COLLEGIUM PHARMACEUTICAL, INC
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Non ST Segment Elevation Acute Coronary Syndrome
- Status
- active
- Trials
- 1